Agenus

If approved, oncology immunotherapies can command strong pricing per course, and neoadjuvant use in high‑risk colon cancer could reach a broad patient base. That said, payer scrutiny, combination regimens, and the need to demonstrate event‑free survival benefit in a curative‑intent setting temper potential.

No approved products today means latent rather than realized pricing power. The randomized MSS mCRC Phase 2 showed 0% ORR in control versus ~19% for BOT 75 mg + BAL, suggesting clinical differentiation if replicated, but regulators have already demanded confirmatory evidence.

Until there is clear, label‑based value, we score realized pricing power as limited.